期刊文献+

替吉奥联合奥沙利铂治疗晚期结肠癌的临床研究 被引量:19

Clinical Research of Advanced Colon Carcinoma Patients Treated with S-1 Combinde with Oxaliplatin
在线阅读 下载PDF
导出
摘要 目的:探讨替吉奥联合奥沙利铂在晚期结肠癌化疗中的近期疗效和毒副反应。方法:97例晚期结肠癌患者,随机分为替吉奥+奥沙利铂组(A组)35例,CapeOX组(B组)32例,mFOLFOX6组(C组)30例,三组分别行相应方案化疗。结果:A组CR2例(5.7%),PR17例(48.6%),B组CR1例(3.1%),PR17例(53.1%),C组CR1例(3.3%),PR13例(43.3%),差异无显著意义(P>0.05),A、B组白细胞减少、恶心呕吐较C组少,手足综合征较C组多,差异有显著意义(P<0.05),而A、B组之间则差异无显著意义(P>0.05);三组在血小板减少、血红蛋白降低、腹泻、口腔炎、肝肾功能损害、周围神经炎等方面差异均无统计学意义(P>0.05)。结论:替吉奥联合奥沙利铂在晚期结肠癌化疗中疗效确切,毒副反应低,临床应用方便,有临床应用价值。 Objective:To evaluate the efficacy and side effects of the combination of S-1 and OXA in the treatment of patients with adnanced colon carcinoma.Methods::97 patients adnanced colon carcinoma were randomized into 3 groups:35 cases in the grouop A(S-1 plus OXA),32 cases in the grouop B(CapeOX) and 30 cases in the grouop C(mFOLFOX6),then received different chemotherapy respectively.Results:In group A,CR was 2 cases(5.7%),PR was 17 cases(48.6%),in group B,CR was 1 case(3.1%),PR was 17 cases(53.1%),and in group C,CR was 1 case(3.3%),PR was 13 cases(43.3%),there was no significant difference amang the 3 groups(P〉0.05).In group and group B had lower rate of leucocytopenia and nausea and vomiting but higher rate of hand-foot syndrome than in group C,with a significant difference(P0.05).The side effects of thrombocytopenia、anaemia、diarrhea、apthous stomatitis、hepatic and renal function and peripheral neuritis had no significant difference amang the 3 groups(P〉0.05).Conclusion:The regimen of S-1 and OXA is effective on treatment of patients with advanced colon carcinoma and the toxicity is mild,and is easy for clinical application.
出处 《中国医药导刊》 2012年第7期1208-1210,共3页 Chinese Journal of Medicinal Guide
关键词 结肠癌 替吉奥 奥沙利铂 化学治疗 Colon carcinoma S-1 Oxaliplatin Chemotherapy
  • 相关文献

参考文献10

  • 1Saltz LB,Clarke S,Diaz-Rubio E,et al.Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:a randomized phase I11 study[J].J Clin Onc01,2008;26:2013-2039.
  • 2Tanaka F, Fukuse T, Wada H,et al.The history,mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic angents[J].Ctirr Pharm Biotechnol,2000;l(2): 137- 164.
  • 3Terashima M,Fujiwara H,Takagane A,et al.Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer[J]. Gastric Cancer,2003;6(Suppl 1):71-81.
  • 4Yoshisue K,Masuda H,Matsushima E,et aI.Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel anfitumor agent(drug combination of tegafur,5-chloro-2,4-dihydroxypyridine,and potassium oxonate) to rats[J].Drug Metab Dipos,2000;28(10): 1162-1167.
  • 5Sato A,Ito T, Tomita T, et al.Chemotherapy of gastric cancer-a review of clinical trial in Japan[J].Gan To Kagaku Ryoho,2002;29(9): 1522-1531.
  • 6Yong Mi Seol.Arol fluoropyrimdines(capecibatine or S-l) and eisplatin as first line treatment in elderly patients with advanced gastric cancer:a retrospective study [J].JPN J Clin OncoI,2009;39(1):43-48.
  • 7李涛,陈凛.SOX方案新辅助化疗应用于进展期胃癌的有效性和安全性研究[J].中华胃肠外科杂志,2011,14(2):104-106. 被引量:77
  • 8王萌,马廷行,李春华,唐晓勇.替吉奥胶囊联合顺铂治疗晚期胃癌28例临床观察[J].中国实用医药,2010,5(12):65-67. 被引量:31
  • 9汪进良,焦顺昌.替吉奥用于非小细胞肺癌治疗的研究及展望[J].中华医学杂志,2010,90(36):2582-2585. 被引量:25
  • 10张璟,黄韬,洪志鹏.替吉奥联合奥沙利铂化疗+三维适形放疗治疗颈段食管癌疗效观察[J].山东医药,2011,51(5):103-103. 被引量:16

二级参考文献35

  • 1Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 2秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:269
  • 3袁泉.羟基脲、替加氟及亚叶酸钙治疗27例晚期鼻咽癌临床观察[J].中国医药导报,2007,4(07Z):54-55. 被引量:14
  • 4Ajanj Ja. Docetaxel for gastric and esophageal carcin om as. Oncology. 2002,16 (6) : 89-96.
  • 5Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-flu-orouracil derivative chemotherapeutic agents: Curr Pharm Biotechnol, 2000,1 ( 2 ) : 137 -164.
  • 6Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil ( capecitabine, UFT, S-1 ) : a review. Oncologist, 2002,7(4) :288-323.
  • 7Diaz-Canton E ,Pazdur R. Preoperative combined oral UFT plus leucovorin and radiation therapy for rectal cancer. Oncology ( Williston Park) ,1997,11 (9 Suppl 10) :58-60.
  • 8Hoff PM. The tegafur based-dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin ( ORZEL ) and S-1 : a review of their clinical development and therapeutic potential. Invest New Drugs,2000,18 (4) :331-342.
  • 9Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities ingastric cance. Gastric Cancer,2003,6( Suppl 1 ) :71-81.
  • 10~oshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5-fluorouracil gastrointestinal (GI) toxicity resulting from the protection of thy- midylate synthase (TS)in GI tissue by repeated repeated simultaneous administration of potassium oxonate ( Oxo ) in rats. Cancer Chemother Pharmacol,2000,46( 1 ) :51-56.

共引文献142

同被引文献115

  • 1鄢俊,钟志宏,施华球.替吉奥联合奥沙利铂治疗结直肠癌的疗效观察[J].医学信息(医学与计算机应用),2014,0(23):98-99. 被引量:1
  • 2吕芳.替吉奥联合奥沙利铂与卡陪他滨联合奥沙利铂治疗晚期结肠癌的疗效与安全性比较[J].医学信息(医学与计算机应用),2014(27):154-154. 被引量:4
  • 3吴邵华.多西他赛联合顺铂治疗47例进展期非小细胞肺癌的疗效观察[J].海南医院学报,2010,16(12):1615-1617.
  • 4Cappuzzo F,Ciuleanu T,Stelmakh L,et al.Erlotinib as maintenance treatment in advanced non-small-cell lung cancer:A multicentre,randomized,placebo-controlled phase 3 study[J].Lancet Oncol,2010,11(6):521-529.
  • 5梁华,张海梅,贺文茜,等.替吉奥联合顺铂与吉西他滨联合顺铂治疗晚期非小细胞肺癌的疗效对比观察[J].中国老年保健学,2012,10(4):101-103.
  • 6Bokemeyer C,Bondarenko I,Hartmann JT,et al.Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4±cetuximab as 1st-line treatment for metastatic colorectal cancer:The OPUS study[J].EJC Suppl,2009,7(2):346.
  • 7Wu XY,Huang XE,You SX,et al.PhaseⅡstudy of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer[J].Asian Pac J Cancer Prev,2013,14(3):2019-2022.
  • 8Tabernero J,Garcia-Carbonero R,Cassidy J,et al.Sorafenib in combination with oxaliplatin,leucovorin,and fluorouracil(modified FOLFOX6)as first-line treatment of metastatic colorectal cancer:the RESPECT trial[J].Clin Cancer Res,2013,19(9):2541-2550.
  • 9Jarmula A. Antifolate inhibitors of thymidylate synthase as anticancer drugs[J]. Mini Rev Med Chem,2010,3:45.
  • 10Gravalos C, Salut A, Garcia - Giron C et al. A randomized phase i1 study to compare oxaliplatin plus 5 - fluorouracil and leucovorin ( FOL- FOX4 ) versus oxaliplatin plus raltitrexed ( TOMOX ) as first- linechemotherapy for advanced colorectal cancer [ J ]. Clin Transl Onco1,2012, Aug, 14 (8) :606-612.

引证文献19

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部